long-acting release drug products for opioid use disorder, chronic pain, and major depressive disorder. Taiwan. 2016. Stemchymal® allogeneic stem cells products. USA. 2018. Immunotherapies for cancer with myeloid checkpoint inhibitors. Taiwan.

Venture and Growth Capital. Overview. Strategies . Overview. ... Healthcare Strategies . We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors. ... primarily in North America and Asia Pacific. We also invest across the ...

Ms. Hsu has 25 years of experience in venture capital, and has participated in the establishment of CDIB Capital Healthcare Ventures and CDIB Capital Healthcare Ventures II since 2012. Career Highlights. Auditor. KPMG. Investment Manager. Central Investment Holding. Senior Vice President.

After joining CDF, Mr. Chang helped raise several private equity/ venture capital funds, including RMB CDIB Private Equity (Fujian) Fund, RMB CDIB Yida Private Equity (Kunshan) Fund, and NTD CDIB Capital Healthcare Venture II, and assisted in CDF’s acquisition of KGI Securities in 2012, Cosmos Bank in 2014 and a 25% stake in China Life in 2017.

About Us. Founded in 1959, we have become a leading equity investment and asset management brand in Asia along the way. learn more.

He oversees CDIB's overall strategy, executive management, and day-to-day operations with a total third party and proprietary AUM of ~US$2.5 billion. Lionel has also played a critical role in CDF's exponential growth from total assets of approximately NT$270 billion in 2006 to NT$3.5 trillion in 2021. Amongst other things, he has driven group ...

Aosheng hi-tech is a leading manufacturer of high-performance composite materials such as carbon fiber and prepreg. Its products are used in wind turbine blade, construction, consumer electronics, healthcare and sporting goods. The company has 15 year of experience in the carbon fiber industry in China.

Steven is based in Taipei and oversees several of CDIB Capital International's direct and third-party private equity fund investments. He led the Jintex (TPEx: 1787) take-private investment, the first leveraged control buyout transaction within the group and also the first succession related domestic take-private buyout. It also won “2019 ...

Stephen is based in Shanghai and leads CDIB Capital International's efforts on portfolio enhancement/value creation, particularly on buyout control investments. He has +25 years of experience in Private Equity, Management Consulting and Fortune 500 executive management with global and Asian responsibilities. Stephen actively participated in ...

Expertise in Buyout and Private Equity Transactions in APAC. Formerly a 20-year veteran at the Carlyle Group focusing on buyout opportunities in Greater China and Southeast Asia. During his tenure at Carlyle Asia, Alex deployed ~US$2.0 billion equity capital in a wide range of industries spanning from media & telecom to financial services ...